UKHSA) is monitoring the effectiveness of the COVID-19 vaccines in the real world as set out in the and has published reports on the impact of the COVID-19 vaccines on:This of the Sanofi/GSK booster (based on the Beta variant) and the Pfizer Original/BA.4-5 bivalent booster (based on the ancestral and BA.4/5 Omicron sub-lineages), given as part of the spring 2023 vaccination programme, amongst those aged 75 years and older in England.This study against hospitalisation, as well as the incremental vaccine effectiveness against hospitalisation of the bivalent BA.1 booster vaccines given as part of the autumn 2022 booster campaign to those aged 50 years or older.The latest evidence shows that is similar for the BA.4/5 variants as it is for BA.2. In somebody who received their second dose around 6 months previously, a booster dose increases protection against hospitalisation by 50% to 60%.